Similarly, survivin-specific inhibitors, such as sepantronium bromide and NSC-80467, likewise restored sensitivity to VenAza and offered meaningful anti-leukemic benefits in TP53 mutant AML [150]. This evidence concerns the gene TP53 and acute myeloid leukemia.